Stock Track | Urogen Pharma Plunges 9.37% Pre-market on Q3 Revenue Miss and Declining Cash Position

Stock Track11-06

Urogen Pharma Ltd. (NASDAQ: URGN) saw its stock plummet 9.37% in pre-market trading, following the release of its third-quarter 2025 financial results. The biopharmaceutical company reported quarterly sales of $27.5 million, falling short of analyst expectations of $33.093 million by 16.90%.

While Urogen's Q3 earnings per share (EPS) of $(0.69) met analyst consensus estimates, investors appeared more concerned with the revenue miss and the company's declining cash position. As of September 30, 2025, Urogen's cash, cash equivalents, and marketable securities totaled $127.4 million, a significant decrease from $241.7 million at the end of 2024. This drop in liquid assets, coupled with a total shareholders' deficit of $115.4 million, may be raising concerns about the company's financial stability.

Despite some positive developments, such as JELMYTO's 13% year-over-year growth in underlying demand revenue and the FDA's agreement to submit a New Drug Application for UGN-103, the overall financial picture seems to have spooked investors. The company's full-year 2025 operating expense guidance of $215 to $225 million, combined with the revenue miss, suggests ongoing challenges in achieving profitability, likely contributing to the sharp pre-market decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103575041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103575041","market":"nz","top_or_hot":-1,"title":"Stock Track | Urogen Pharma Plunges 9.37% Pre-market on Q3 Revenue Miss and Declining Cash Position","media":"Stock Track","content":"<p>Urogen Pharma Ltd. (NASDAQ: URGN) saw its stock plummet 9.37% in pre-market trading, following the release of its third-quarter 2025 financial results. The biopharmaceutical company reported quarterly sales of $27.5 million, falling short of analyst expectations of $33.093 million by 16.90%.</p>\n\n<p>While Urogen's Q3 earnings per share (EPS) of $(0.69) met analyst consensus estimates, investors appeared more concerned with the revenue miss and the company's declining cash position. As of September 30, 2025, Urogen's cash, cash equivalents, and marketable securities totaled $127.4 million, a significant decrease from $241.7 million at the end of 2024. This drop in liquid assets, coupled with a total shareholders' deficit of $115.4 million, may be raising concerns about the company's financial stability.</p>\n\n<p>Despite some positive developments, such as JELMYTO's 13% year-over-year growth in underlying demand revenue and the FDA's agreement to submit a New Drug Application for UGN-103, the overall financial picture seems to have spooked investors. The company's full-year 2025 operating expense guidance of $215 to $225 million, combined with the revenue miss, suggests ongoing challenges in achieving profitability, likely contributing to the sharp pre-market decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Urogen Pharma Plunges 9.37% Pre-market on Q3 Revenue Miss and Declining Cash Position</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Urogen Pharma Plunges 9.37% Pre-market on Q3 Revenue Miss and Declining Cash Position\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 21:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Urogen Pharma Ltd. (NASDAQ: URGN) saw its stock plummet 9.37% in pre-market trading, following the release of its third-quarter 2025 financial results. The biopharmaceutical company reported quarterly sales of $27.5 million, falling short of analyst expectations of $33.093 million by 16.90%.</p>\n\n<p>While Urogen's Q3 earnings per share (EPS) of $(0.69) met analyst consensus estimates, investors appeared more concerned with the revenue miss and the company's declining cash position. As of September 30, 2025, Urogen's cash, cash equivalents, and marketable securities totaled $127.4 million, a significant decrease from $241.7 million at the end of 2024. This drop in liquid assets, coupled with a total shareholders' deficit of $115.4 million, may be raising concerns about the company's financial stability.</p>\n\n<p>Despite some positive developments, such as JELMYTO's 13% year-over-year growth in underlying demand revenue and the FDA's agreement to submit a New Drug Application for UGN-103, the overall financial picture seems to have spooked investors. The company's full-year 2025 operating expense guidance of $215 to $225 million, combined with the revenue miss, suggests ongoing challenges in achieving profitability, likely contributing to the sharp pre-market decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"URGN","symbol_name":"乌龙制药","start_time":0,"source_url":"","article_id":"1103575041","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103575041","pubTimestamp":1762434759,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Urogen Pharma Ltd. (NASDAQ: URGN) saw its stock plummet 9.37% in pre-market trading, following the release of its third-quarter 2025 financial results. The biopharmaceutical company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"URGN":"乌龙制药"},"translate_title":"个股追踪|Urogen Pharma盘前暴跌9.37%，因Q3营收未达预期且现金头寸下降","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"URGN":1},"content_text":"Urogen Pharma Ltd. (NASDAQ: URGN) saw its stock plummet 9.37% in pre-market trading, following the release of its third-quarter 2025 financial results. The biopharmaceutical company reported quarterly sales of $27.5 million, falling short of analyst expectations of $33.093 million by 16.90%.\nWhile Urogen's Q3 earnings per share (EPS) of $(0.69) met analyst consensus estimates, investors appeared more concerned with the revenue miss and the company's declining cash position. As of September 30, 2025, Urogen's cash, cash equivalents, and marketable securities totaled $127.4 million, a significant decrease from $241.7 million at the end of 2024. This drop in liquid assets, coupled with a total shareholders' deficit of $115.4 million, may be raising concerns about the company's financial stability.\nDespite some positive developments, such as JELMYTO's 13% year-over-year growth in underlying demand revenue and the FDA's agreement to submit a New Drug Application for UGN-103, the overall financial picture seems to have spooked investors. The company's full-year 2025 operating expense guidance of $215 to $225 million, combined with the revenue miss, suggests ongoing challenges in achieving profitability, likely contributing to the sharp pre-market decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103575041","isCrawlerRequest":true}